1
|
Barbieri E, Pozzi S, Gelmini R, Roncati L, Maccaferri M, Potenza L, Marasca R, Luppi M, Leonardi G. PEG-Asparaginase Single-Agent Rescue in an Advanced Case of Monomorphic Epitheliotropic Intestinal T Cell Lymphoma. J Gastrointest Cancer 2022; 54:304-308. [PMID: 35230648 DOI: 10.1007/s12029-022-00808-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/19/2022] [Indexed: 11/29/2022]
Abstract
PURPOSE MEITL is a very rare and highly aggressive peripheral T cell lymphoma with poor prognosis and for which there is no standard treatment. Treatment options for patients patients with relapsed/refractory disease are scarce and the choice of an appropriate rescue still represents an unmet need. METHODS Here, we report the case of a 65-year-old woman affected by MEITL, progressing after initial treatment with an anthracycline-based chemotherapy and surgery, who received single-agent PEG-asparaginase salvage therapy at our institution. RESULTS PEG-asparaginase single-agent rescue proved to be rapidly effective in controlling the disease and its associated paraneoplastic features. Nevertheless, toxicity was high and the patient died due to a treatment-related complication. CONCLUSION The case we described brings new evidences on the effectiveness of PEG-asparaginase therapy in MEITL patients. Whether PEG-asparaginase should be included in the treatment course of MEITL patients could be the subject of future studies.
Collapse
|
2
|
Martinez-Calle N, Kirkwood AA, Lamb M, Smith A, Khwaja J, Manos K, Shrubsole C, Gray N, Lewis K, Tivey A, Bishton MJ, Hawkes E, Ahearne MJ, Osborne W, Collins GP, Illidge T, Linton KM, Cwynarski K, Burton C, Fox CP. Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Adv Ther 2021; 38:3789-3802. [PMID: 34037958 PMCID: PMC8280044 DOI: 10.1007/s12325-021-01764-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Accepted: 04/28/2021] [Indexed: 12/28/2022]
Abstract
INTRODUCTION Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine practice, to serve as a benchmark analysis for comparison BV-CHP efficacy in routine practice. METHODS Patients aged 16 years or older with sALCL treated in seven UK and Australian centres and from 14 additional centres from the UK Haematological Malignancy Research Network database (n = 214). Treatment allocation was clinician choice and included best supportive care (BSC). Main outcomes were time to treatment failure (TTF) and overall survival (OS). Multivariable analysis for predictors of both TTF and OS was also undertaken. RESULTS The median age 52 years (range 16-93), 18% ECOG ≥ 3 and 40% of cases were ALK positive. CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) was employed in 152 (71%) of patients and CHOEP (CHOP + etoposide) in 4% of patients. For CHOP-treated patients overall response rate (ORR) was 65% and complete response (CR) 47%. Only 9% of patients underwent autologous stem cell transplant (ASCT). With 57 months median follow-up, 4-year TTF and OS were 41.2% (95% CI 33.1-49.1) and 58.9% (95% CI 50.3-66.5) respectively. Multivariable analysis showed ALK+ status was independently associated with superior TTF (HR 0.36, 95% CI 0.21-0.63) but not OS (0.44, 95% CI 0.18-1.07). DISCUSSION We present a retrospective analysis with mature follow-up of one of the largest multicentre populations of sALCL available, comparable to similar large retrospective studies. ALK status remains a strong predictor of outcomes. CONCLUSION These data serve as a robust benchmark for BV-CHP as the new standard of care for sALCL. Similar real-world evidence with BV-CHP will be desirable to confirm the findings of ECHELON-2.
Collapse
Affiliation(s)
- Nicolas Martinez-Calle
- Russell Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK.
| | - Amy A Kirkwood
- CRUK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - Maxine Lamb
- Haematological Malignancy Research Network, University of York, York, UK
| | - Alex Smith
- Haematological Malignancy Research Network, University of York, York, UK
| | - Jahanzaib Khwaja
- University College of London Hospitals, NHS Foundation Trust, London, UK
| | | | | | - Nicola Gray
- Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | | | - Ann Tivey
- Cancer Sciences, University of Manchester and the Christie, NHS Foundation Trust, Manchester, UK
| | - Mark J Bishton
- Russell Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK
| | - Eliza Hawkes
- Olivia Newton-John Cancer Research Institute, Austin, Australia
| | | | - Wendy Osborne
- Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
| | | | - Timothy Illidge
- Cancer Sciences, University of Manchester and the Christie, NHS Foundation Trust, Manchester, UK
| | - Kim M Linton
- Cancer Sciences, University of Manchester and the Christie, NHS Foundation Trust, Manchester, UK
| | - Kate Cwynarski
- University College of London Hospitals, NHS Foundation Trust, London, UK
| | | | - Christopher P Fox
- Russell Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK
| |
Collapse
|
3
|
Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. Virchows Arch 2018; 473:749-757. [PMID: 30151671 PMCID: PMC6267266 DOI: 10.1007/s00428-018-2434-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Revised: 08/03/2018] [Accepted: 08/07/2018] [Indexed: 01/07/2023]
Abstract
Granulysin is a cytolytic protein expressed in cytotoxic T and natural killer (NK) cells. Abnormal serum levels of granulysin in lymphomas with NK and cytotoxic phenotype have been shown to correlate with tumour progression. In this study, we investigated the expression pattern of granulysin in routine sections of normal and reactive lymphoid tissues as well as in a large series of lymphomas. In normal tissues, granulysin labelled a small population of cells that double immunostaining revealed to belong to the pool of cytotoxic T/NK cells. Among lymphoid neoplasms, the highest expression of granulysin (71%) was found in extranodal NK/T cell lymphomas of nasal type (ENKTL). To note is that 29% of ENKTLs, which were negative for one or more of classical cytotoxic markers strongly expressed granulysin. Furthermore, expression of granulysin was observed in rare cases of T cell lymphomas with a cytotoxic phenotype (i.e. ALK-negative anaplastic large cell lymphoma (26%), enteropathy-associated T cell lymphoma (12%) and peripheral T cell lymphoma, NOS (4%)). None of the investigated non-Hodgkin B cell lymphomas, Hodgkin lymphoma and plasma cell myeloma were granulysin positive. The results suggest granulysin as a novel marker for a subset of cytotoxic NK cell derived malignancies and its usefulness is highlighted in those ENKTLs that lack expression of other cytotoxic markers but retain granulysin expression.
Collapse
|
4
|
Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, Abarah W, Choufi B, Pham AD, Gac AC, Fruchart C, Marin E, Safar V, Parcelier A, Maisonneuve H, Bachy E, Cartron G, Jaccard A, Tournilhac O, Rossi C, Schirmer L, Martignoles JA, Gaulard P, Tilly H, Damaj G. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget 2018; 7:85573-85583. [PMID: 27458168 PMCID: PMC5356759 DOI: 10.18632/oncotarget.10764] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Accepted: 07/10/2016] [Indexed: 12/15/2022] Open
Abstract
Peripheral T-cell lymphoma (PTCL) is a group of diseases with poor outcome and few therapeutic options. We aimed to assess the efficacy of bendamustine in real life cohort of patients. Between November 2009 and March 2015, 138 PTCL patients were treated with bendamustine in 27 centers. Population median age was 64 (28-89) years with male/female ratio of 1.4. There were mainly angio-immunoblastic (AITL = 71), PTCL-not otherwise specified (PTCL-NOS = 40) and anaplastic large cell lymphoma (ALCL = 8). The majority of patients (96%) had disseminated disease and extranodal localizations (77%). Median number of chemotherapy lines prior to bendamustine was 2 (1-8). Median duration of response (DoR) after the last chemotherapy prior to bendamustine was 4.3 months (1-70) and 50% of patients had refractory disease. Median number of administered bendamustine cycles was 2 (1-8) and 72 patients (52%) received less than 3 mostly because of disease progression. Median dose was 90 (50-150) mg/m². Overall response rate (ORR) was 32.6% with complete response (CR) rate of 24.6% and median DoR was 3.3 months (1-39). AITL patients were more sensitive than PTCL-NOS patients (ORR: 45.1 versus 20%, p = 0.01). Median PFS and OS were 3.1 (0.2-46.3) and 4.4 (0.2-55.4) months. On multivariate analysis, refractory disease (p = 0.001) and extranodal localization (p = 0.028) adversely influenced ORR. Grade 3-4 thrombocytopenia, neutropenia and infections were reported in 22, 17 and 23% of cases respectively. Bendamustine as single agent could be considered as a therapeutic option for relapsed or refractory PTCL, particularly in chemosensitive or AITL patients. Combinations of bendamustine with other drugs warrant further evaluation.
Collapse
Affiliation(s)
| | - Fabien Le Bras
- Department of Hematology, Assistance Publique des Hôpitaux de Paris, Créteil, France
| | - Charles Herbaux
- Department of Hematology, University and Regional Hospital of Lille, Lille, France
| | - Emmanuel Gyan
- Department of Hematology, University Hospital of Tours, UMR CNRS, Tours, France
| | - Aline Clavert
- Department of Hematology, University Hospital of Angers, Angers, France
| | - Franck Morschhauser
- Department of Hematology, University and Regional Hospital of Lille, Lille, France
| | - Sandra Malak
- Department of Hematology, Institut Curie, Paris, France
| | - David Sibon
- Department of Hematology, Hôpital Necker-Enfants Malades, Paris, France
| | | | - Thorsten Braun
- Department of Hematology, Hôpital Avicenne, Bobigny, France
| | | | - Reda Garidi
- Department of Hematology, Saint Quentin Hospital, Saint Quentin, France
| | - Sabine Tricot
- Department of Hematology, Centre Hospitalier Valenciennes, Valenciennes, France
| | - Roch Houot
- Department of Hematology, University Hospital Pontchaillot, Rennes, France
| | - Bertrand Joly
- Department of Hematology, Centre Hospitalier Sud Francilien, Corbeil, France
| | - Wajed Abarah
- Department of Hematology, Meaux Hospital, Meaux, France
| | - Bachra Choufi
- Department of Hematology, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France
| | - Anne-Dominique Pham
- Department of Biostatistics and Clinical Research, University Hospital of Caen, Caen, France
| | - Anne-Claire Gac
- Department of Hematology, University Hospital of Caen, Caen, France
| | | | - Emilie Marin
- Department of Hematology, University Hospital of Caen, Caen, France
| | - Violaine Safar
- Department of Hematology, Hospices Civils de Lyon, Pierre-Benite, France
| | - Anne Parcelier
- Department of Hematology, University Hospital of Amiens, Amiens, France
| | - Hervé Maisonneuve
- Department of Hematology, La Roche-sur-Yon Hospital, La Roche sur-Yon, France
| | - Emmanuel Bachy
- Department of Hematology, Hospices Civils de Lyon, Pierre-Benite, France
| | - Guillaume Cartron
- Department of Hematology, Université Montpellier, CHRU, UMR CNRS, Montpellier, France
| | - Arnaud Jaccard
- Department of Hematology, University Hospital of Limoges, Limoges, France
| | - Olivier Tournilhac
- Department of Hematology, University Hospital of Clermont-Ferrand, Clermont Ferrand, France
| | - Cédric Rossi
- Department of Hematology, University Hospital of Dijon, Dijon, France
| | - Luciane Schirmer
- Department of Hematology, University Hospital of Nancy, Vandoeuvre Les Nancy, France
| | - Jean-Alain Martignoles
- Department of Hematology, Institut de Cancérologie Lucien Neuwirth, Saint-Etienne, France
| | - Philippe Gaulard
- Department of Pathology, University Paris Est, Hôpital Henri Mondor, Créteil, France
| | - Hervé Tilly
- Department of Hematology, Centre Henri Becquerel, Rouen, France
| | - Gandhi Damaj
- Department of Hematology, University Hospital of Caen, Caen, France.,Microenvironnement Cellulaire et Pathologies, Normandie University, UNICAEN, MILPAT, Caen, France
| | | |
Collapse
|
5
|
Guolo F, Ferrari M, Minetto P, Matteo C, Clavio M, Coviello E, Ballerini F, Miglino M, Gobbi M, D'Incalci M, Lemoli RM, Zucchetti M. Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas. Hematol Oncol 2017; 36:498-499. [PMID: 29052244 DOI: 10.1002/hon.2484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2017] [Revised: 10/01/2017] [Accepted: 10/03/2017] [Indexed: 11/06/2022]
Affiliation(s)
- Fabio Guolo
- Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'OncologiaT, Genoa, Italy
| | - Mariella Ferrari
- Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - Paola Minetto
- Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'OncologiaT, Genoa, Italy
| | - Cristina Matteo
- Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - Marino Clavio
- Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'OncologiaT, Genoa, Italy
| | - Elisa Coviello
- Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'OncologiaT, Genoa, Italy
| | - Filippo Ballerini
- Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'OncologiaT, Genoa, Italy
| | - Maurizio Miglino
- Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'OncologiaT, Genoa, Italy
| | - Marco Gobbi
- Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'OncologiaT, Genoa, Italy
| | - Maurizio D'Incalci
- Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - Roberto Massimo Lemoli
- Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'OncologiaT, Genoa, Italy
| | - Massimo Zucchetti
- Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| |
Collapse
|
6
|
Gentille C, Qin Q, Barbieri A, Ravi PS, Iyer S. Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. Ecancermedicalscience 2017; 11:771. [PMID: 29062389 PMCID: PMC5636209 DOI: 10.3332/ecancer.2017.771] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Indexed: 12/14/2022] Open
Abstract
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), previously known as enteropathy associated T-cell lymphoma (EATL) type II, is a rare haematological malignancy with a difficult and delayed diagnosis. Symptoms can include abdominal pain, weight loss, and chronic diarrhoea. However, most patients are only diagnosed after complications, such as perforation or obstruction, have developed. There is no standard treatment for MEITL; most accepted regimens consist of surgical resection and anthracycline-based chemotherapy. Prognosis is poor with an approximate survival of less than a year. Even though other therapies, such as autologous stem cell transplant, has shown promising results, not all patients can tolerate this course of treatment especially if they are elderly, have several comorbidities or are malnourished. Innovative therapies that improve survival and can be used as an alternative for more intensive treatment are needed. We report the use of PEG-asparaginase along with conventional anthracycline therapy in a 70-year-old woman diagnosed with MEITL, who went into remission and survived for more than one year before succumbing to relapsed disease.
Collapse
Affiliation(s)
- Cesar Gentille
- Department of Internal Medicine, Houston Methodist Hospital, Houston, Texas 77030, USA
| | - Qian Qin
- Department of Internal Medicine, Houston Methodist Hospital, Houston, Texas 77030, USA
| | - Andreia Barbieri
- Department of Pathology, Houston Methodist Hospital, Houston, Texas 77030, USA
| | - Pingali Sai Ravi
- Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, Texas 77030, USA
| | - Swaminathan Iyer
- Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, Texas 77030, USA
| |
Collapse
|
7
|
Conduit C, Harrup R, Ragg S, Johnston A. An audit of patients with mature T-cell non-Hodgkin lymphoma by transplant status in Tasmania. Intern Med J 2017; 47:464-466. [PMID: 28401714 DOI: 10.1111/imj.13390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Revised: 10/20/2016] [Accepted: 01/09/2017] [Indexed: 10/19/2022]
Abstract
This retrospective audit of patients diagnosed with mature T-cell lymphoma across a 10-year period provides contemporary information on the outcomes and treatment patterns of an Australian cohort. Forty-two patients diagnosed with mature T-cell lymphoma were identified from the Tasmanian Cancer Registry and analysed using medical records and simple statistical analysis. The demographics and outcomes of patients in this cohort were comparable to large international studies with treatment patterns in line with the best available evidence.
Collapse
Affiliation(s)
- Ciara Conduit
- Department of Clinical Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia
| | - Rosemary Harrup
- Department of Clinical Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.,School of Medicine, University of Tasmania, Hobart, Tasmania, Australia
| | - Scott Ragg
- Department of Clinical Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.,Department of Pathology, Royal Hobart Hospital, Hobart, Tasmania, Australia
| | - Anna Johnston
- Department of Clinical Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.,School of Medicine, University of Tasmania, Hobart, Tasmania, Australia
| |
Collapse
|
8
|
Bledsoe AC, Zakko L, Loftus CG. 76-Year-Old Man With Abdominal Pain, Fever, and Maculopapular Rash. Mayo Clin Proc 2016; 91:1114-7. [PMID: 27236425 DOI: 10.1016/j.mayocp.2016.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/23/2016] [Revised: 02/23/2016] [Accepted: 03/01/2016] [Indexed: 10/21/2022]
Affiliation(s)
- Adam C Bledsoe
- Resident in Internal Medicine, Mayo School of Graduate Medical Education, Rochester, MN
| | - Liam Zakko
- Fellow in Gastroenterology and Hepatology, Mayo School of Graduate Medical Education, Rochester, MN
| | - Conor G Loftus
- Advisor to resident and fellow and Consultant in Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
| |
Collapse
|
9
|
First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J 2016; 6:e452. [PMID: 27471868 PMCID: PMC5030384 DOI: 10.1038/bcj.2016.63] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Accepted: 06/20/2016] [Indexed: 12/15/2022] Open
Abstract
Current guidelines recommend consolidation with autologous stem cell transplantation (autoSCT) after induction chemotherapy for most patients with peripheral T-cell lymphoma (PTCL). This assumption is based on five prospective phase II studies, three of which included <50 patients with limited follow-up. Here we present the final analysis of the prospective German study. The treatment regimen consisted of four to six cycles of CHOP chemotherapy followed by mobilizing therapy and stem cell collection. Patients in complete remission (CR) or partial remission (PR) underwent myeloablative chemo(radio)therapy and autoSCT. From January 2001 to July 2010, 111 patients were enrolled in the study. The main subgroups were PTCL not specified (n=42) and angioimmunoblastic T-cell lymphoma (n=37). Seventy-five (68%) of the 111 patients received transplantation. The main reason for not receiving autoSCT was progressive disease. In an intent-to-treat analysis, the complete response rate after myeloablative therapy was 59%. The estimated 5-year overall survival, disease-free survival and progression-free survival rates were 44%, 54% and 39%, respectively. The results of this study confirm that upfront autoSCT can result in long-term remissions in patients with all major subtypes of PTCL and therefore should be part of first-line therapy whenever possible.
Collapse
|
10
|
Biology of peripheral T cell lymphomas – Not otherwise specified: Is something finally happening? ACTA ACUST UNITED AC 2016. [DOI: 10.1016/j.pathog.2016.02.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
11
|
Dupuis J, Morschhauser F, Ghesquières H, Tilly H, Casasnovas O, Thieblemont C, Ribrag V, Bossard C, Le Bras F, Bachy E, Hivert B, Nicolas-Virelizier E, Jardin F, Bastie JN, Amorim S, Lazarovici J, Martin A, Coiffier B. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. LANCET HAEMATOLOGY 2015; 2:e160-5. [PMID: 26687958 DOI: 10.1016/s2352-3026(15)00023-x] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 11/28/2014] [Revised: 02/12/2015] [Accepted: 02/16/2015] [Indexed: 10/23/2022]
Abstract
BACKGROUND Romidepsin is a histone deacetylase inhibitor approved in the USA for patients with recurrent or refractory peripheral T-cell lymphoma and has shown activity in this setting with mainly haematological and gastrointestinal toxicity. Although it has limited efficacy, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used for treatment of de-novo peripheral T-cell lymphoma. We aimed to assess the safety, tolerability, and activity of romidepsin combined with CHOP in patients with previously untreated disease. METHODS We enrolled patients aged 18-80 years with histologically proven, previously untreated, peripheral T-cell lymphoma (Eastern Cooperative Oncology Group performance status ≤2) into a dose-escalation (phase 1b) and expansion (phase 2) study at nine Lymphoma Study Association centres in France. In the dose-escalation phase, we allocated consecutive blocks of three participants to receive eight 3 week cycles of CHOP (intravenous cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), and vincristine 1.4 mg/m(2) [maximum 2 mg] on day 1 and oral prednisone 40 mg/m(2) on days 1-5) in association with varying doses of romidepsin. The starting dose was 10 mg/m(2) intravenously on days 1 and 8 of each cycle, and we used a 3 + 3 design. We assessed dose-limiting toxicities only during the first two cycles. The primary endpoint was to determine the recommended dose for the combination. For the phase 2 study, we aimed to increase the cohort of patients receiving the recommended dose to a total of 25 patients. Patients were assessed for safety outcomes at least twice per cycle according to the Common Terminology Criteria for Adverse Events, version 4.0. Safety analyses included all patients who received at least one dose of romidepsin and CHOP. This trial is registered at the European Clinical Trials Database (EudraCT), number 2010-020962-91 and ClinicalTrials.gov, number NCT01280526. FINDINGS Between Jan 13, 2011, and May 21, 2013, we enrolled 37 patients (18 treated in phase 1b and 19 patients in phase 2). Three of six patients initially treated at 10 mg/m(2) had a dose-limiting toxicity. The dose-escalation committee decided to modify the study protocol to redefine dose-limiting toxicities with regard to haematological toxicity. Three patients were treated with 8 mg/m(2) of romidepsin, an additional three at 10 mg/m(2) (one dose-limiting toxicity), and six patients at 12 mg/m(2) (three dose-limiting toxicities). We chose romidepsin 12 mg/m(2) as the recommended dose for phase 2. Of the 37 patients treated, three had early cardiac events (two myocardial infarctions and one acute cardiac failure). No deaths were attributable to toxicity. 25 (68%) of 37 patients had at least one serious adverse event. Overall, the most frequent serious adverse events were febrile neutropenia (five [14%] of 37 patients), physical health deterioration (five [14%]), lung infection (four [11%]), and vomiting (three [8%]). 33 (89%) of patients had grade 3-4 neutropenia, and 29 (78%) had grade 3-4 thrombocytopenia. INTERPRETATION Romidepsin can be combined with CHOP but this combination should now be tested in comparison to CHOP alone in a randomised trial. FUNDING Celgene.
Collapse
Affiliation(s)
- Jehan Dupuis
- Lymphoid Malignancies Unit, Henri Mondor University Hospital, Créteil, France
| | - Franck Morschhauser
- Department of Hematology, GRITA Unit, Claude Huriez University Hospital, Lille, France
| | | | - Hervé Tilly
- Department of Hematology, Henri Becquerel Cancer Center, Rouen, France
| | | | | | - Vincent Ribrag
- Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France
| | - Céline Bossard
- Department of Pathology, Hôtel Dieu University Hospital, Nantes, France
| | - Fabien Le Bras
- Lymphoid Malignancies Unit, Henri Mondor University Hospital, Créteil, France
| | - Emmanuel Bachy
- Department of Hematology, Hospices Civils de Lyon and University Lyon 1, Lyon, France
| | - Bénédicte Hivert
- Department of Hematology, GRITA Unit, Claude Huriez University Hospital, Lille, France
| | | | - Fabrice Jardin
- Department of Hematology, Henri Becquerel Cancer Center, Rouen, France
| | | | - Sandy Amorim
- Department of Hematology-Oncology, Saint Louis Hospital, Paris, France
| | - Julien Lazarovici
- Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France
| | - Antoine Martin
- Department of Pathology, Avicenne University Hospital, Bobigny, France
| | - Bertrand Coiffier
- Department of Hematology, Hospices Civils de Lyon and University Lyon 1, Lyon, France.
| |
Collapse
|